Cytokinetics finds a new partner in Greater China for its potential blockbuster drug — it could be one of a handful of ...

Apollomics Inc., a late-stage clinical biopharmaceutical company, said its leukemia drug failed to pass trials in China, a ...

China is going to be brimming with foreign brands showcasing their goods next year. Consumer-goods expos will be running throughout the year for products including dining ware, cosmetics, food and ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...

China’s aggressive drive to replace brand-name foreign drugs with dirt-cheap homegrown generics has already taken a toll on ...

Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. The new ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

China's homegrown medicines are expected to play a more important role in tumor treatment as domestic researchers and ...

On December 10, JD Health, in collaboration with Merck, a globally renowned biopharmaceutical leader, began offering ...